In vitro activity of Ro 24-6392, a novel ester-linked co-drug combining ciprofloxacin and desacetylcefotaxime.
In preliminary in vitro susceptibility tests Ro 24-6392 (desacetylcefotaxime with a 3'-ciprofloxacin substitution) demonstrated activity against a wide spectrum of aerobic bacteria, 98.6% of strains being inhibited by less than or equal to 8 mg/l. Of the commonly isolated species tested, only enterococcal strains were resistant (MICs greater than or equal to 32 mg/l). The potency of Ro 24-6392 was generally between that observed for the two hydrolysis components, except in the case of Providencia stuartii and penicillin-resistant pneumococci isolates which were more susceptible to Ro 24-6392. This new dual-action compound appears to be slightly more active than the previously studied peer drug Ro 23-9424, principally because of the superior activity of the fluoroquinolone component, ciprofloxacin.
Jones
R N
RN
Clinical Microbiology Institute, Tualatin, Oregon 97062.
D000890:Anti-Infective Agents; D002439:Cefotaxime / Q000031:analogs & derivatives* / Q000494:pharmacology; D002939:Ciprofloxacin / Q000031:analogs & derivatives* / Q000494:pharmacology; D024841:Fluoroquinolones; D008826:Microbial Sensitivity Tests
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; C065470:Ro 24-6392; D002939:Ciprofloxacin; D002439:Cefotaxime